Navigation Links
FDA Clears New Immune Response Claim for the CryoValve(R) SG Pulmonary Human Heart Valve
Date:2/17/2009

for use in soft tissue repair. CryoLife distributes Hemostase MPH(R), a hemostatic agent, in much of the U.S. for use in cardiac and vascular surgery and in the United Kingdom, Germany, France, and Canada for cardiac, vascular, and general surgery, subject to certain exclusions.

Statements made in this press release that look forward in time or that express management's beliefs, expectations or hopes are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include those regarding the expected benefits of the CryoValve SG and its potential impact on patients as well as the factors considered by surgeons when replacing a pulmonary valve. These forward looking statements may not occur as, when or to the extent expected, and are subject to a number of risk, including the following: CryoValve SG continues to undergo testing, and additional test results may not yield the anticipated benefits. Many factors impact the suitability of patients for transplants, and there can be no guaranty that patients who receive the CryoValve SG will be more likely to be considered suitable for transplants or have better results following a transplant. In addition, the factors considered by surgeons in weighing transplant options may vary and may change over time. The Company does not undertake to update its forward-looking statements.

For additional information about the company, visit CryoLife's Web site: http://www.cryolife.com.

    Media Contacts:
    D. Ashley Lee
    Executive Vice President, Chief Financial Officer and
    Chief Operating Officer
    Phone: 770-419-3355

    Katie Brazel
    Fleishman Hillard
    Phone: 404-739-0150

'/>"/>
SOURCE CryoLife, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Abbott Acquisition of Advanced Medical Optics Clears U.S. Antitrust Review
2. FDA Clears Expanded Labeling for the Invisalign System
3. FDA Clears the DPL (Deep Penetrating Light) Therapy System for Over-the-Counter - Home Use
4. FDA Clears NeuroStar(R) TMS Therapy for the Treatment of Depression
5. Dutch Authorize Manufacture of Vaccinogens New Cancer Vaccine; License Clears Path to European Production, Final FDA Trial
6. Genetic Information Nondiscrimination Act clears Senate
7. Alzheimers vaccine clears plaque but has little effect on learning and memory impairment
8. ClearScript Offers Innovative Medication Therapy Management Program to Employee Health Plans
9. FDA Clears Cellsearch(TM) Circulating Tumor Cell Test for Monitoring Metastatic Prostate Cancer Patients
10. Congress Clears the Way for National CPR and AED Awareness Week
11. American Medical Association Clears Path for Adenoviral Conjunctivitis - Pink Eye - Detector
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2014)... Sunday 31 August 2014: Mortality and morbidity of ... despite good use of oral anticoagulants, according to the ... Pilot Registry. The findings were presented for the first ... Professor Gregory Lip (Birmingham, UK). , Professor Lip said: ... on management practices of European cardiologists conducted since the ...
(Date:8/30/2014)... Spain Sunday 31 August 2014: A new ... and powered by heart motion was presented at ... Switzerland. The prototype device does not require battery ... the Cardiovascular Engineering Group at ARTORG, University of ... in today,s medical implants. Once they reach a ...
(Date:8/30/2014)... In a world where a typical response to conflict is ... a game app to teach another way. Launched in ... is a colorful way to encourage moral values playfully. ... double-duty by teaching players new ways to find happiness and ... for consistently taking the high road, the Ultimate Karma game ...
(Date:8/30/2014)... Atlanta based automotive group Jim Ellis Automotive joined ... awareness for ALS by participating in the popular ALS ... Vice President Jimmy Ellis all participated in the challenge ... on their Youtube page; https://www.youtube.com/watch?v=pxufyxVo9j0 . , In ... staff also took the opportunity to challenge various businesses ...
(Date:8/30/2014)... Denver, Colorado (PRWEB) August 30, 2014 The ... modeling the body that will reveal to users some shocking ... lead to great results in modeling looks, as well as ... the new method says that there is one unique trick ... new method indicates that despite what many people might think, ...
Breaking Medicine News(10 mins):Health News:AF mortality and morbidity high at 1 year despite good anticoagulant use 2Health News:Batteryless cardiac pacemaker is based on automatic wristwatch 2Health News:Newly Launched Ultimate Karma App Elicits Happiness in Players and Encourages Moral Values 2Health News:Jim Ellis Automotive Group Take the ALS Ice Bucket Challenge 2Health News:Truth about Six Pack Abs Review Reveals Unique Method to Eliminate Stubborn Stomach Fat 2
... AND EFFECTIVE FOR COPD , Previous research has ... risk for adverse events or respiratory-related death in patients ... (COPD); however, a recent article shows this may not ... Spain, Argentina, and Uruguay reviewed the results of 27 ...
... research suggests that high-risk women with breast cancer who do ... for developing a second breast cancer than previously thought. ... sentinel node biopsy be considered at the time of prophylactic ... findings? , The increased risk of developing breast cancer ...
... could help bridge this knowledge gap, experts say , , ... of babies have a surprisingly low knowledge of child ... know or how they should act, a new study ... parents don,t know that 1-year-olds can,t tell the difference ...
... hospitalizing young children for influenza creates a significant economic ... preventive flu shots for children and the people with ... by Cincinnati Childrens Hospital Medical Center and presented May ... Honolulu, Hawaii. , After analyzing data in three U.S. ...
... surprisingly low-level knowledge of typical infant development and ... emotional growth, according research from the University of ... false parenting assumptions can not only impair parent-child ... stimulation, will be presented Sunday, May 4, at ...
... designed to block the neurotransmitter acetylcholine including common ... are more likely to be dependent in one or ... according to new findings from researchers at Wake Forest ... which involve a class of drugs known as anticholinergic ...
Cached Medicine News:Health News:News briefs: May issue of the journal Chest 2Health News:Second breast cancer may be greater than thought for high-risk women without BRCA mutations 2Health News:One-Third of Parents Lack Facts About Child Development 2Health News:One-Third of Parents Lack Facts About Child Development 3Health News:Young children hospitalized for flu associated with higher costs and higher risk illness 2Health News:Nearly one-third of US parents don't know what to expect of infants 2Health News:Commonly used medications associated with impaired physical function in older adults 2
(Date:8/29/2014)... , Aug. 29, 2014 Pomerantz LLP has ... or the "Company") (NASDAQ: EDAP ) and ... United States District Court, Southern District of ... on behalf of a class consisting of all persons ... 2013 and July 30, 2014, inclusive (the "Class Period"). This ...
(Date:8/29/2014)... Calif. , Aug. 29, 2014 Thoratec ... in device-based mechanical circulatory support therapies to save, support ... participating in the 2014 Morgan Stanley Global Healthcare Conference ... Burbach , President and Chief Executive Officer, will provide ... Eastern Daylight Time (9:55 a.m., Pacific Daylight Time).   ...
(Date:8/29/2014)... 29, 2014 Research and Markets  has announced ... Insight 2014" report to their offering. ... one of the largest segments of pharmaceuticals industry. The numbers ... the available therapies were unable to meet the market requirements. ... for CNS disorder, especially over the past two decades. The ...
Breaking Medicine Technology:SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against EDAP TMS S.A. and Certain Officers - EDAP 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against EDAP TMS S.A. and Certain Officers - EDAP 3US CNS Disorders Drug Pipeline Insight 2014 2
... The annual meeting of the Chinese food industry is ... June, heavily focusing on the growing health market in China, and ... and discuss business developments in the country and beyond. ... and China continues to enjoy a global reputation for being a ...
... Amgen (Nasdaq: AMGN ) today announced the ... compared XGEVA ™ (denosumab) to Zometa ® (zoledronic ... 1,901 men with prostate cancer and bone metastases. The study, ... secondary endpoints and demonstrated XGEVA,s superiority compared to Zometa in ...
Cached Medicine Technology:Health on the Agenda at Food ingredients Asia-China Trade Show 2Results Published in The Lancet Demonstrate Superiority of XGEVA™ (Denosumab) in the Prevention of Bone Complications for Men With Bone Metastases From Advanced Prostate Cancer 2Results Published in The Lancet Demonstrate Superiority of XGEVA™ (Denosumab) in the Prevention of Bone Complications for Men With Bone Metastases From Advanced Prostate Cancer 3Results Published in The Lancet Demonstrate Superiority of XGEVA™ (Denosumab) in the Prevention of Bone Complications for Men With Bone Metastases From Advanced Prostate Cancer 4Results Published in The Lancet Demonstrate Superiority of XGEVA™ (Denosumab) in the Prevention of Bone Complications for Men With Bone Metastases From Advanced Prostate Cancer 5Results Published in The Lancet Demonstrate Superiority of XGEVA™ (Denosumab) in the Prevention of Bone Complications for Men With Bone Metastases From Advanced Prostate Cancer 6Results Published in The Lancet Demonstrate Superiority of XGEVA™ (Denosumab) in the Prevention of Bone Complications for Men With Bone Metastases From Advanced Prostate Cancer 7Results Published in The Lancet Demonstrate Superiority of XGEVA™ (Denosumab) in the Prevention of Bone Complications for Men With Bone Metastases From Advanced Prostate Cancer 8Results Published in The Lancet Demonstrate Superiority of XGEVA™ (Denosumab) in the Prevention of Bone Complications for Men With Bone Metastases From Advanced Prostate Cancer 9
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: